TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Association Between the Transcranial Direct Current Stimulation (tDCS) and Functional Electrical Stimulation (FES) for Upper-limb Rehabilitation After Stroke - A Randomized Clinical Trial
Brief Summary: The aim of this study is to verify the effectiveness of tDCS combined with FES on upper limb rehabilitation of post-stroke subjects with moderate and severe compromise.


Options:
A: Arm Label: Real stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Arm Label: Sham stimulation; Type: SHAM_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Intervention Type: DEVICE; Name: tdcs (ELDITH, Neuroconn, Ilmenau, Germany); Assigned to Arm(s): Real stimulation, Sham stimulation
B: Arm Label: Functional electrical stimulation (FES); Type: ACTIVE_COMPARATOR; Interventions: Device: Functional Electrical Stimulation (FES) | Arm Label: Combination of transcranial direct current stimulation and FES; Type: EXPERIMENTAL; Interventions: Device: Combination of Transcranial direct brain stimulation (tDCS) and FES | Intervention Type: DEVICE; Name: Functional Electrical Stimulation (FES); Assigned to Arm(s): Functional electrical stimulation (FES) | Intervention Type: DEVICE; Name: Combination of Transcranial direct brain stimulation (tDCS) and FES; Assigned to Arm(s): Combination of transcranial direct current stimulation and FES
C: Arm Label: real-tDCS with MI-BCI; Type: ACTIVE_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Arm Label: sham-tDCS with MI-BCI; Type: SHAM_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Intervention Type: DEVICE; Name: real-tDCS with MI-BCI; Assigned to Arm(s): real-tDCS with MI-BCI, sham-tDCS with MI-BCI
D: Arm Label: tDCS & epidermis anesthesia & repeated passive movement; Type: EXPERIMENTAL; Interventions: Device: tDCS, Drug: Epidermis anesthesia, Other: Repeated passive movement | Arm Label: Shame tDCS & sham anesthesia & repeated passive movement; Type: SHAM_COMPARATOR; Interventions: Drug: sham anesthesia, Other: Repeated passive movement, Device: sham tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): tDCS & epidermis anesthesia & repeated passive movement | Intervention Type: DRUG; Name: Epidermis anesthesia; Assigned to Arm(s): tDCS & epidermis anesthesia & repeated passive movement | Intervention Type: DRUG; Name: sham anesthesia; Assigned to Arm(s): Shame tDCS & sham anesthesia & repeated passive movement | Intervention Type: OTHER; Name: Repeated passive movement; Assigned to Arm(s): Shame tDCS & sham anesthesia & repeated passive movement, tDCS & epidermis anesthesia & repeated passive movement | Intervention Type: DEVICE; Name: sham tDCS; Assigned to Arm(s): Shame tDCS & sham anesthesia & repeated passive movement

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PRIMM Trial (Phone Reminder for IMMunization) in Ondo State, Nigeria
Brief Summary: The purpose of this study is to determine if in a rural setting of Ondo State, Nigeria, a customized automated telephone and email immunization reminder system will be feasible, acceptable, and significantly improve immunization utilization rates.


Options:
A: Arm Label: Kilkari; Type: EXPERIMENTAL; Interventions: Other: Kilkari | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Kilkari; Assigned to Arm(s): Kilkari
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: A customized windows® software application | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: A customized windows® software application; Assigned to Arm(s): Intervention
C: Intervention Type: DRUG; Name: Sulfadoxine pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: Identification and registration of pregnant women and servic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh | Arm Label: Birth notification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh | Arm Label: Childhood vaccination services under EPI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh | Arm Label: Newly married couple identification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh | Arm Label: e-Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh | Arm Label: e-monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh | Intervention Type: BEHAVIORAL; Name: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh; Assigned to Arm(s): Birth notification, Childhood vaccination services under EPI, Identification and registration of pregnant women and servic, Newly married couple identification, e-Referral, e-monitoring

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Universal Medication Schedule to Promote Adherence to Complex Drug Regimens
Brief Summary: This study will leverage available technologies and test strategies to impart the Universal Medication Schedule (UMS) in primary care to help patients understand, consolidate, safely use, and adhere to their complex medication regimens.


Options:
A: Arm Label: Motivational interview; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interview | Intervention Type: BEHAVIORAL; Name: Motivational interview; Assigned to Arm(s): Motivational interview
B: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
C: Arm Label: Diabetes Medication Choice Decision Aid; Type: EXPERIMENTAL; Interventions: Other: Diabetes Medication Choice decision aid | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice Decision Aid
D: Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text or Portal; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EHR + (Text or Portal) | Intervention Type: BEHAVIORAL; Name: EHR + (Text or Portal); Assigned to Arm(s): Text or Portal

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TEC4Home: Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring
Brief Summary: Modern technology like computers, smartphones and the Internet enable patients to measure certain health indicators, like blood pressure and body weight, from the comfort of their own homes. This information can also be shared electronically with doctors and other healthcare providers to monitor remotely. This is called home health monitoring. In TEC4Home, we are developing a home monitoring solution for patients with heart failure to support their care and recovery at home after a visit to the emergency department. We hope to show that this solution decreases revisits to the emergency department and increases quality of life for patients.


Options:
A: Arm Label: Current Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Care Transition Intervention; Type: EXPERIMENTAL; Interventions: Other: Structured Telephone / Remote Outpatient Monitoring | Intervention Type: OTHER; Name: Structured Telephone / Remote Outpatient Monitoring; Assigned to Arm(s): Care Transition Intervention
B: Arm Label: Hip Hop Stroke educational program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hip Hop Stroke educational program | Arm Label: Nutrition Education program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Nutrition Education program | Intervention Type: BEHAVIORAL; Name: Hip Hop Stroke educational program; Assigned to Arm(s): Hip Hop Stroke educational program | Intervention Type: BEHAVIORAL; Name: Nutrition Education program; Assigned to Arm(s): Nutrition Education program
C: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Remote Patient Monitoring | Intervention Type: DEVICE; Name: Remote Patient Monitoring; Assigned to Arm(s): Home Telemonitoring
D: Arm Label: Current treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: A package of interventions; Type: OTHER; Interventions: Other: A package of interventions | Intervention Type: OTHER; Name: A package of interventions; Assigned to Arm(s): A package of interventions

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian
Brief Summary: This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Arm B, Arm C | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm B, Arm C
B: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy
C: Arm Label: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active comparator: Niraparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Active comparator: Niraparib; Assigned to Arm(s): Niraparib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian
Brief Summary: This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.


Options:
A: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
B: Arm Label: vargatef/Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: vargatef | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vargatef; Assigned to Arm(s): vargatef/Nintedanib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian
Brief Summary: This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
B: Arm Label: Combination navicixizumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Arm Label: Paclitaxel monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Xerna™ TME Panel | Arm Label: Navicixizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Intervention Type: DRUG; Name: navicixizumab; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy | Intervention Type: DEVICE; Name: Xerna™ TME Panel; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy, Paclitaxel monotherapy
C: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Refinement and Evaluation of a Multilevel Intervention for Preventing Men's Use of Violence in Urban South Africa (Sonke CHANGE Trial)
Brief Summary: South Africa has one of the highest rates of violence towards women globally. However, little is known about how to prevent men's use of violence. The Sonke CHANGE Trial tests an intervention that targets men as individuals, groups, and community members in a peri-urban setting in South Africa. Eighteen neighborhoods will be randomly assigned to either the intervention condition or a control group. By speaking to men at baseline, 12 months, and 24 months, investigators will learn whether violence and other health behaviors shift over time. Alongside the trial, qualitative research will explore how the intervention took place and why participants may change attitudes or behaviors.


Options:
A: Arm Label: Assignment to FORNET; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: FORNET | Arm Label: Assignment to CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Arm Label: Waiting List Control Group (camp); Type: OTHER; Interventions: Other: Waiting List Control Group (camp) | Arm Label: Waiting List Control Group (no camp); Type: OTHER; Interventions: Other: Waiting List Control Group (no camp) | Intervention Type: BEHAVIORAL; Name: FORNET; Assigned to Arm(s): Assignment to FORNET | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): Assignment to CBT | Intervention Type: OTHER; Name: Waiting List Control Group (camp); Assigned to Arm(s): Waiting List Control Group (camp) | Intervention Type: OTHER; Name: Waiting List Control Group (no camp); Assigned to Arm(s): Waiting List Control Group (no camp)
B: Arm Label: Sonke CHANGE intervention condition; Type: EXPERIMENTAL; Interventions: Other: Sonke CHANGE intervention | Arm Label: Control condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Sonke CHANGE intervention; Assigned to Arm(s): Sonke CHANGE intervention condition
C: Arm Label: FSI-ECD; Type: EXPERIMENTAL; Interventions: Behavioral: Family Strengthening Intervention for Early Childhood Development | Arm Label: Control; Type: OTHER; Interventions: Other: Community Health Worker Routine | Intervention Type: BEHAVIORAL; Name: Family Strengthening Intervention for Early Childhood Development; Assigned to Arm(s): FSI-ECD | Intervention Type: OTHER; Name: Community Health Worker Routine; Assigned to Arm(s): Control
D: Arm Label: Step-by-Step; Type: EXPERIMENTAL; Interventions: Behavioral: Step-by-Step | Arm Label: Enhanced care as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced care as usual | Intervention Type: BEHAVIORAL; Name: Step-by-Step; Assigned to Arm(s): Step-by-Step | Intervention Type: BEHAVIORAL; Name: Enhanced care as usual; Assigned to Arm(s): Enhanced care as usual

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smart Walk: A Physical Activity Program for African American Women
Brief Summary: The purpose of this project is to test an 8-month, culturally relevant, Smartphone-delivered PA program to improve and maintain high physical levels and reduce cardiometabolic disease risk among obese AA women.


Options:
A: Arm Label: Smartphone App Participants (APP); Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone App Participants (APP) | Arm Label: Diabetes Prevention Program Participants (DPP); Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Prevention Program Participants (DPP) | Intervention Type: BEHAVIORAL; Name: Smartphone App Participants (APP); Assigned to Arm(s): Smartphone App Participants (APP) | Intervention Type: BEHAVIORAL; Name: Diabetes Prevention Program Participants (DPP); Assigned to Arm(s): Diabetes Prevention Program Participants (DPP)
B: Arm Label: Physical Activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Wellness Contact Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Wellness; Assigned to Arm(s): Wellness Contact Control
C: Arm Label: Aim2Be Live Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Aim2Be app with Live Coach + Fitbit + BMI tracking tools | Arm Label: Aim2Be Waitlist; Type: OTHER; Interventions: Behavioral: Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools | Intervention Type: BEHAVIORAL; Name: Aim2Be app with Live Coach + Fitbit + BMI tracking tools; Assigned to Arm(s): Aim2Be Live Coach | Intervention Type: BEHAVIORAL; Name: Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools; Assigned to Arm(s): Aim2Be Waitlist
D: Arm Label: HABIT Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HABIT | Arm Label: TRE Group; Type: EXPERIMENTAL; Interventions: Behavioral: TRE | Intervention Type: BEHAVIORAL; Name: TRE; Assigned to Arm(s): TRE Group | Intervention Type: BEHAVIORAL; Name: HABIT; Assigned to Arm(s): HABIT Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Supporting Patient Activation in Transition to Home (sPATH) Intervention - a Study Protocol of Randomized Controlled Trial
Brief Summary: This study evaluates if motivational interviewing sessions aiming to motivate recently discharged patients with either chronic obstructive pulmonary disease or congestive heart failure to be active in post-discharge self-management can reduce re-hospitalization rates.


Options:
A: Arm Label: Care Management+Community Health Worker; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management+Community Health Worker | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management+Community Health Worker; Assigned to Arm(s): Care Management+Community Health Worker | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Comprehensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes, Drug: Antiplatelet Agents, Drug: Beta Blocker, Drug: ACE Inhibitors | Arm Label: Less Intensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes | Intervention Type: BEHAVIORAL; Name: Lifestyle Changes; Assigned to Arm(s): Comprehensive Intervention Group, Less Intensive Intervention Group | Intervention Type: DRUG; Name: Antiplatelet Agents; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: Beta Blocker; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: ACE Inhibitors; Assigned to Arm(s): Comprehensive Intervention Group
C: Arm Label: sPATH; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): sPATH
D: Arm Label: STRIP intervention; Type: EXPERIMENTAL; Interventions: Other: STRIP intervention | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: STRIP intervention; Assigned to Arm(s): STRIP intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: C